Pullix (PLX) has recently taken centre stage in the DeFi market. Many analysts have this Stage 6 presale project pegged as the next 100x altcoin in 2024. But can it leave renowned players like Injective (INJ) and Ripple (XRP) in the dust? Today, we will look at all three of these DeFi coins and find out.
Pullix (PLX) is grabbing attention as it has already provided early backers with a 100% ROI. Because of this, millions of global traders are flooding this new ICO event, which has already raised $3.6M.
Investors are intrigued by this DeFi project since it could revolutionize online trading. Pullix will establish the world’s first hybrid trading platform that combines the best of DEX and CEX. This innovative approach will remove many issues that affect this market. For example, you won’t worry about high trading fees as Pullix requires 0% commissions on trades.
Additionally, other intriguing aspects may excite traders, such as:
The PLX native token is the main currency used to trade on Pullix. Moreover, PLX is the very first “Trade-to-Earn” crypto. You will receive a daily percentage of Pullix’s revenue if you stake this altcoin. The team will also implement a burn feature, drastically reducing the PLX supply and increasing its value – great news for long-term PLX token holders.
Due to all these reasons, over 69M PLX tokens have been sold so far. Currently, one PLX costs just $0.08, but its value will rise as the presale advances. Market analysts forecast a 100x surge once this altcoin hits exchanges in Q1 of 2024. This price prediction is very possible with ties to the OTC derivatives market, valued at $618T in 2022.
Meanwhile, the past week saw some exciting Injective news as it released the new Volan Upgrade. According to its official announcement, this upgrade will redefine real-world assets, institutional adoption, scalability, and more on Injective.
In terms of the Injective coin value movement, it has been on an uptrend recently. We can see that it has pumped by 28% on the monthly chart. This altcoin has fluctuated between $31 and $39 during that time. Similarly, the Injective market cap has risen from $2.59B to $3.3B.
With 24 green technical indicators, market analysts predict Injective will trade at the $53.99 level within Q2 of 2024.
The Ripple XRP Healthcare (XRPH) has announced its latest feat as a validator node within the XRP Ledger (XRPL) network. This noteworthy accomplishment shows the platform’s dedication to transparency.
The Ripple crypto has been trading in the green on the weekly charts. It has moved between the $0.56 and $0.57 levels. Meanwhile, its market cap has jumped from $30.66B to $31.45B during that time.
As this altcoin trades above its 100 and 200-day EMAs, experts are confident that Ripple may surge to $0.81 within Q2 of 2024.
Looking at all of these altcoins, it is clear that Pullix has a competitive advantage – its low market cap. It now sits at $16M, meaning it would only need another $16M for its current price to double. Therefore, this new ICO will provide faster and more significant gains than Injective and Ripple.
Solana network has recorded a spike in demand from institutional investors amid anticipated approval of…
Strategy missed Wall Street expectations by a huge margin during the first quarter. Saylor expects…
Kraken is preparing to go public in the near future via an IPO. The surge…
A consistent close above the resistance range between 19 cents and 20 cents will trigger…
The crypto market capitalization has surged back above $3 trillion, displaying the growing strength within…
Tether, the company behind the USDT stablecoin, said it had nearly $120 billion invested in…
